Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on August 05, 2019, 11:15:29 am
-
The Food and Drug Administration (FDA) has approved AbbVie’s Mavyret (glecaprevir/pibrentasvir) to treat all six genotypes of hepatitis C virus (HCV) among adolescents.
Mavyret was approved to treat all genotypes of HCV among adults in August 2017.
The adolescent approval is based on clinical trials including 47 adolescents with genotype 1, 2, 3 or 4 of hep C who had no cirrhosis or only a mild case. All those who received the regimen for eight or 16 weeks achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure).
For more....
https://www.hepmag.com/article/fda-oks-abbvies-mavyret-adolescents-hepatitis-c